10 realities MPN clients require to understand about FDA approval of Ropegylated interferon alpha2b (Besremi).

Ruben Mesa, MD, FACP, executive director of Mays Cancer Center, house to UT Health San Antonio MD Anderson Cancer Center, and MPN specialist and private investigator, goes over the top 10 truths that clients with myeloproliferative neoplasms (specifically those with polycythemia vera) require to understand about the FDA approval of Ropegylated interferon alpha2b (Besremi).

Follow Dr. Mesa on Twitter @mpdrc.

Check out cancer.uthscsa.edu to find out more about the Mays Cancer.

Follow Mays Cancer Center on social networks.
Facebook: UTHealthsaMDAnderson
Instagram: UTHealthsaMDAnderson
Twitter: @UTHealthSAMDA.

http://phlebotomycareertraining.org/10-realities-mpn-clients-require-to-understand-about-fda-approval-of-ropegylated-interferon-alpha2b-besremi/